Honghui Zhou - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Honghui Zhou

Showing results (141-150 of 143) with videos related to

Pageof 15

Sort By:

You have reached the last page of results.This site can display upto 143 results.

Clinical Pharmacokinetics|October 7, 2017

Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple MyelomaXiaoyu Yan, Pamela L Clemens, Thomas Puchalski, et al.

Mabs|June 4, 2010

Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor αDavid J Shealy, Ann Cai, Kim Staquet, et al.

Targeted Oncology|September 15, 2023

Population Pharmacokinetics and Exposure-Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1Xin Miao, Liviawati S Wu, Shun Xin Wang Lin, et al.

Pageof 15

Search research articles

Showing results (141-150 of 143) with videos related to

Sort By:

Pageof 15

You have reached the last page of results.This site can display upto 143 results.

Clinical Pharmacokinetics|October 7, 2017

Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple MyelomaXiaoyu Yan, Pamela L Clemens, Thomas Puchalski, et al.

Mabs|June 4, 2010

Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor αDavid J Shealy, Ann Cai, Kim Staquet, et al.

Targeted Oncology|September 15, 2023

Population Pharmacokinetics and Exposure-Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1Xin Miao, Liviawati S Wu, Shun Xin Wang Lin, et al.

Pageof 15